Introduction: Use of Digital therapeutics can act as a valuable tool enabling more personalized care among diabetics. The Breathe Diabetes Management Program (BDMP) delivers personalized interventions encouraging them to track their blood glucose level, weight, and physical activity.

Objective: To assess BDMP app in type 2 diabetics in achieving healthy outcomes in Indian population.

Methodology: The group of participants (N=181, A1C >6.5%) was divided into 3 groups - (1) patients treated with the BDMP plus Doctor-prescribed medication (n=60), (2) patients treated with the BDMP plus Doctor-prescribed medication plus Stress Reduction module (n=61) and (3) patients only taking the Doctor-prescribed medication (control group with n=60).

Results: At the end of the 16 weeks, patients from Group 1 showed 81.6% program completion rate, 46.01% program adherence, an average of 5.64% of baseline body weight loss, an average of 0.68% reduction in A1C and Penn State Worry Questionnaire (PSWQ) score average change from 56.3 to 44.5 (score ranges 16-80, higher score indicates higher worry). Patients from Group 2 showed 88.5% program completion rate, 51.95% program adherence, an average of 6.02% of baseline body weight loss, average of 0.74% reduction in A1C and a PSWQ score average change from 58.6 to 40.8. Patients from Group 3 showed an average of 0.38% of baseline body weight loss, average of 0.28% reduction in A1C and a PSWQ score average change from 56.2 to 55.5. The difference between all the groups was found to be statistically significant (p<0.05).

Conclusion: The BDMP helped the patients of Group 1 in significant weight loss, reduction in A1C, and improved stress levels. BDMP along with the Stress Reduction module in Group 2 produced even better outcomes. The results suggest that Digital Therapeutics is a scalable and sustainable solution to the growing problem of type 2 diabetes, and that mental well-being should be considered a part of the solution.

Disclosure

P. K. Goyal: None. R. Verma: None. A. Kaicker: None. S. Deka: None. S. Palukuri: None. B. Chandolia: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.